BCL-2 is an anti-apoptotic protein involved in mitochondrial outer membrane integrity, and its inhibition by venetoclax serves as a therapeutic option in chronic lymphocytic leukaemia, acute myeloid leukaemia, and other diseases. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.